Globus Medical (GMED) to Release Earnings on Thursday

Globus Medical (NYSE:GMED) is anticipated to post its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect Globus Medical to post earnings of $0.79 per share and revenue of $734.5760 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, August 7th. The medical device company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.10. The business had revenue of $745.34 million for the quarter, compared to the consensus estimate of $738.91 million. Globus Medical had a net margin of 13.58% and a return on equity of 10.65%. The company’s revenue was up 18.4% compared to the same quarter last year. During the same period last year, the firm posted $0.75 earnings per share. On average, analysts expect Globus Medical to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Globus Medical Stock Down 2.1%

GMED opened at $61.45 on Thursday. The company has a market cap of $8.30 billion, a price-to-earnings ratio of 23.63, a PEG ratio of 1.72 and a beta of 1.12. Globus Medical has a 52-week low of $51.79 and a 52-week high of $94.93. The firm’s fifty day simple moving average is $59.40 and its two-hundred day simple moving average is $60.26.

Insider Activity at Globus Medical

In other news, Director Ann D. Rhoads sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $58.46, for a total value of $584,600.00. Following the completion of the transaction, the director owned 25,384 shares of the company’s stock, valued at approximately $1,483,948.64. This trade represents a 28.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 18.51% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GMED. EverSource Wealth Advisors LLC boosted its stake in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the period. Headlands Technologies LLC lifted its stake in Globus Medical by 485.4% in the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock worth $45,000 after acquiring an additional 631 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in Globus Medical by 237.3% in the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after acquiring an additional 598 shares during the last quarter. EP Wealth Advisors LLC purchased a new position in Globus Medical in the second quarter worth approximately $200,000. Finally, Cresset Asset Management LLC purchased a new position in Globus Medical in the second quarter worth approximately $211,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on GMED shares. Needham & Company LLC reissued a “hold” rating on shares of Globus Medical in a research note on Monday, July 21st. Canaccord Genuity Group decreased their price target on shares of Globus Medical from $97.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, July 22nd. Royal Bank Of Canada set a $88.00 price target on shares of Globus Medical in a research note on Friday, October 10th. Wells Fargo & Company cut their price objective on shares of Globus Medical from $76.00 to $66.00 and set an “overweight” rating for the company in a research report on Friday, August 8th. Finally, Morgan Stanley cut their price objective on shares of Globus Medical from $75.00 to $68.00 and set an “overweight” rating for the company in a research report on Tuesday, July 15th. Seven analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.55.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.